About
Cancer Immunotherapy
Areas of Focus
Categories
Biologics & BiopharmaceuticalSouthwestern U.S.
Clinical Trials (8)
View allTotal Trials
8
As Lead Sponsor
3
As Collaborator
5
Total Enrollment
93
By Phase
NA: 1PHASE1/PHASE2: 1PHASE2: 2PHASE1: 4
By Status
COMPLETED: 4TERMINATED: 2RECRUITING: 1WITHDRAWN: 1
Clinical Trials Pipeline8 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT06693297Collaborator
Immediate Versus Conventional Loading of Early Placed Dental Implant Supporting Single Crowns
NARecruiting
40 participants
Started: Sep 25, 2024 · Completed: Sep 30, 2026
NCT02719015Collaborator
Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma
PHASE1/PHASE2Withdrawn
Started: Mar 31, 2018 · Completed: Mar 31, 2022
NCT00942409Collaborator
Study of Repeat Intranodal Injections of Ad-ISF35
PHASE2Terminated
5 participants
Started: Jun 30, 2009 · Completed: Jul 31, 2014
NCT00849524Collaborator
Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
PHASE2Terminated
6 participants
Started: Jan 31, 2009 · Completed: Jul 31, 2014
NCT00772486Lead Sponsor
A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL
PHASE1Completed
13 participants
Started: Sep 30, 2008 · Completed: Apr 30, 2013
Funding History (1)
D
Jan 5, 2012
Locations (1)
Headquarters
Houston, TX, United States
Map
Loading map...